BT063 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2

49. 全身性エリテマトーデス

---

臨床試験数 : 946 /  薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02554019 (ClinicalTrials.gov)	September 28, 2015	16/9/2015	Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus	A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Biological: BT063;Biological: Placebo	Biotest	NULL	Completed	18 Years	75 Years	All	36	Phase 2	Belarus;Georgia;Poland;Serbia
2	EUCTR2014-005526-35-PL (EUCTR)	12/09/2015	10/08/2015	Clinical study to evaluate the safety and tolerability of treatment with BT063 versus Placebo in Subjects with Systemic Lupus Erythematosus (BT063 in SLE)	A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated dose, Multicentre Phase IIa Proof-of-Concept Study with BT063 in Subjects with Systemic Lupus Erythematosus (BT063 in SLE)	Systemic Lupus Erythematosus MedDRA version: 19.1;Level: LLT;Classification code 10042947;Term: Systemic lupus erythematosus synd;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BT063 Product Code: BT063 INN or Proposed INN: BT063 Other descriptive name: BT063	Biotest AG	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 2	Serbia;Belarus;Poland;Georgia